Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunosuppressive agents for treating IgA nephropathy.

J A Samuels1, G F M Strippoli, J C Craig

  • 1Nephrology / Pediatric Nephrology, UT-Houston Health Science Center, 6431 Fannin Street, MSB 4-148, Houston, TX 77030, USA. Joshua.A.Samuels@uth.tmc.edu

The Cochrane Database of Systematic Reviews
|October 30, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High-Target Hemodiafiltration Convective Dose Achieved in Most Patients in a 6-Month Intermediary Analysis of the CONVINCE Randomized Controlled Trial.

Kidney international reports·2023
Same author

Pandemic and bills: The impact of COVID-19 on energy usage of schools in South Africa.

Energy for sustainable development : the journal of the International Energy Initiative·2021
Same author

NMR-based metabolomic study of Apulian Coratina extra virgin olive oil extracted with a combined ultrasound and thermal conditioning process in an industrial setting.

Food chemistry·2020
Same author

Multiple rare genetic variants co-segregating with familial IgA nephropathy all act within a single immune-related network.

Journal of internal medicine·2016
Same author

COGNITIVE-HD study: protocol of an observational study of neurocognitive functioning and association with clinical outcomes in adults with end-stage kidney disease treated with haemodialysis.

BMJ open·2015
Same author

Patient classification and outcome prediction in IgA nephropathy.

Computers in biology and medicine·2015

Immunosuppressive treatments, particularly steroids, show promise in slowing IgA nephropathy (IgAN) progression and reducing protein in urine. However, optimal management and patient selection require further research due to study limitations.

Area of Science:

  • Nephrology
  • Immunology
  • Clinical Trials

Background:

  • IgA nephropathy (IgAN) is a significant global cause of end-stage renal failure (ESRF).
  • Established treatments for IgAN are lacking, prompting investigation into various therapeutic approaches.

Purpose of the Study:

  • To evaluate the efficacy and safety of immunosuppressive therapies for IgA nephropathy.
  • To synthesize evidence from randomized controlled trials (RCTs) on immunosuppressive treatments for IgAN.

Main Methods:

  • Systematic review and meta-analysis of RCTs and quasi-RCTs.
  • Searched multiple databases including Cochrane, MEDLINE, and EMBASE up to September 2002.
  • Data extraction and quality assessment performed independently by two reviewers.

Related Experiment Videos

Main Results:

  • Thirteen RCTs with 623 patients were analyzed.
  • Steroid treatment reduced the risk of progression to ESRF and urinary protein excretion.
  • Alkylating agents/cyclosporin also decreased urinary protein excretion compared to placebo.

Conclusions:

  • Immunosuppressive interventions, especially steroids, appear beneficial for IgAN.
  • Optimal management and patient subgroups that benefit most require further investigation.
  • High-quality RCTs are needed to clarify treatment benefits and harms.